Repligen Announces Agreement to Acquire ARTeSYN Biosolutions slide image

Repligen Announces Agreement to Acquire ARTeSYN Biosolutions

Strategic Move to Expand Single-Use Bioprocessing Systems, Components and Flow Paths R REPLIGEN 3 Gold Standard in Single-Use Systems ARTESYN Biosolutions is an innovator and a market leader in fully automated CGMP single-use Chromatography, Filtration and Buffer/Media Prep Systems and Flow Paths Vertical Integration with EMT and ProConnex® EMT key provider of silicone liners and assemblies (July 2020) Complements and expands ProConnex flow paths Full control of supply chain Complements, Expands RGEN's Systems Portfolio beyond Hollow Fiber Filtration Adds Systems for Flat sheet Filtration, Chromatography and Buffer Prep Adds leading innovator in downstream continuous manufacturing Future integration of FlowVPE to further differentiate RGEN Systems Foundation for Systems in Gene Therapy Filtration and Chromatography solutions Very low hold up volumes - minimizes product losses and differentiates versus competition Expands Total Addressable Market Adds ~$0.2B to addressable market bringing total to ~$3.2B Addresses all biologic types mAbs ● ● rProteins Vaccines Cell & Gene Therapy Meets Repligen's M&A Criteria Highly differentiated technology Addresses gaps in Filtration and Chromatography Systems Strong revenue growth Accretive to adj. EPS in 2022 Market leader, SU innovator, Expands RGEN Systems, Accretive 2022 ARTESYN Biosolutions
View entire presentation